Junshi Biosciences Collaborated with Dr. Reddy’s to Develop and Commercialize Toripalimab for the Treatment of Cancer
Shots:
- Junshi will receive ~$728.3M up front & milestones along with royalties on the net sales of products containing toripalimab (anti-PD-1 mAb)
- Under the license & commercialization agreement, Dr. Reddy’s gets the rights to develop & commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India & South Africa & may also elect to expand the scope of the license to cover Australia, New Zealand & 9 other countries
- If Junshi decides to grant any third party the rights to commercialize 2 other products in 1+ countries within the total of 21 countries of Dr. Reddy's Territory, Dr. Reddy's also receives an exclusive right of first negotiation for commercialization
Ref: Globenewswire | Image: Junshi Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
